No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.

BACKGROUND Low-molecular-weight heparin (LMWH) is a popular alternative to unfractionated heparin (UH) for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), in part based on the perception of a lower risk for heparin-induced thrombocytopenia (HIT). To investigate the evidence supporting this perception, we performed a metaanalysis to compare the incidence of thrombocytopenia between LMWH and UH during PE and/or DVT treatment. METHODS Randomized trials comparing LMWH with UH for PE and/or DVT treatment were searched for in the MEDLINE database, bibliographies, and by correspondence with published investigators. Two reviewers independently selected high-quality studies and extracted data regarding heparin-associated thrombocytopenia (HAT), HIT confirmed by laboratory testing, and heparin-induced thrombocytopenia with thrombosis (HITT). Outcome rates between LMWH and UH were compared using a binomial, generalized linear mixed model with a logit link and Gaussian random effects for study. RESULTS Thirteen studies involving 5,275 patients met inclusion criteria. There were no statistically significant differences in HAT rates between the two treatments (LMWH, 1.2%; UH, 1.5%; p = 0.246). The incidence of documented HIT and HITT was too low to make an adequate comparison between groups. CONCLUSIONS Our review disclosed no statistically significant difference in HAT between LMWH and UH and insufficient evidence to conclude that HIT and HITT rates were different between them. There was no evidence from randomized comparative trials to support the contention that patients receiving treatment for PE or DVT with UH are more prone to these complications than those receiving LMWH.

[1]  S. Smith.  Commentary. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. , 2007, Perspectives in vascular surgery and endovascular therapy.

[2]  R. Levine,et al.  How frequently is venous thromboembolism in heparin-treated patients associated with heparin-induced thrombocytopenia? , 2006, Chest.

[3]  J. Douketis,et al.  Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular- Weight Heparin for Acute Treatment of Venous Thromboembolism , 2006 .

[4]  P. Wells,et al.  Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. , 2005, Blood.

[5]  Giancarlo Agnelli,et al.  Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[6]  P. Prandoni,et al.  Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. , 2004, Archives of internal medicine.

[7]  V. Kakkar,et al.  Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis , 2003, Thrombosis and Haemostasis.

[8]  E. Lindhoff‐Last,et al.  Incidence and clinical relevance of heparin‐induced antibodies in patients with deep vein thrombosis treated with unfractionated or low‐molecular‐weight heparin , 2002, British journal of haematology.

[9]  A Agresti,et al.  On Small‐Sample Confidence Intervals for Parameters in Discrete Distributions , 2001, Biometrics.

[10]  L. Brown,et al.  Interval Estimation for a Binomial Proportion , 2001 .

[11]  V. Kakkar,et al.  Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. , 2001, The New England journal of medicine.

[12]  R. Yusen,et al.  Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease , 2001, Annals of Internal Medicine.

[13]  P. Horsewood,et al.  Impact of the patient population on the risk for heparin-induced thrombocytopenia , 2000 .

[14]  H. Büller,et al.  Fixed-dose, Body Weight-independent Subcutaneous LMW Heparin versus Adjusted Dose Unfractionated Intravenous Heparin in the Initial Treatment of Proximal Venous Thrombosis , 2000, Thrombosis and Haemostasis.

[15]  Y. Gruel,et al.  Affinity purification of heparin‐dependent antibodies to platelet factor 4 developed in heparin‐induced thrombocytopenia: biological characteristics and effects on platelet activation , 2000, British journal of haematology.

[16]  J. Douketis,et al.  A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. , 2000, Archives of internal medicine.

[17]  Peter Horsewood, John G. Kelton.  Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia , 2000, Platelets.

[18]  B. Chong,et al.  Further characterization of antibody and antigen in heparin‐induced thrombocytopenia , 1999, British journal of haematology.

[19]  J. Fareed,et al.  Functional Heterogeneity of Antiheparin-Platelet Factor 4 Antibodies: Implications in the Pathogenesis of the HIT Syndrome , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[20]  J. Michiels,et al.  Normal Life Expectancy and Thrombosis-Free Survival in Aspirin Treated Essential Thrombocythemia , 1999, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[21]  Y. Shoenfeld,et al.  Defining an Antigenic Epitope on Platelet Factor 4 Associated With Heparin-Induced Thrombocytopenia , 1998 .

[22]  H. Breddin,et al.  Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. , 1998, International angiology : a journal of the International Union of Angiology.

[23]  Y. Gruel,et al.  Differences in specificity of heparin‐dependent antibodies developed in heparin‐induced thrombocytopenia and consequences on cross‐reactivity with danaparoid sodium , 1997, British journal of haematology.

[24]  J. Kelton,et al.  The epitope specificity of heparin‐induced thrombocytopenia , 1996, British journal of haematology.

[25]  David B. Dunson,et al.  Bayesian Data Analysis , 2010 .

[26]  J. Fiessinger,et al.  Once-daily Subcutaneous Dalteparin, a Low Molecular Weight Heparin, for the Initial Treatment of Acute Deep Vein Thrombosis , 1996, Thrombosis and Haemostasis.

[27]  M. Horne,et al.  Platelet binding of IgG from patients with heparin-induced thrombocytopenia. , 1996, The Journal of laboratory and clinical medicine.

[28]  P. Bossuyt,et al.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. , 1996, The New England journal of medicine.

[29]  J. Hirsh,et al.  A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. , 1996, The New England journal of medicine.

[30]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[31]  M. Bloch,et al.  Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. , 1993, Thrombosis research.

[32]  J. Vandenbroucke,et al.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis , 1992, The Lancet.

[33]  S. Lopaciuk,et al.  Subcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial , 1992, Thrombosis and Haemostasis.

[34]  O. Hélénon,et al.  Randomized Trial of Subcutaneous Low‐Molecular‐Weight Heparin CY 216 (Fraxiparine) Compared With Intravenous Unfractionated Heparin in the Curative Treatment of Submassive Pulmonary Embolism: A Dose‐Ranging Study , 1992, Circulation.

[35]  H. Büller,et al.  Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis , 1992, The Lancet.

[36]  J. Sixma,et al.  Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study. , 1989, Circulation.

[37]  J. Amiral.  Antigens involved in heparin-induced thrombocytopenia. , 1999, Seminars in hematology.

[38]  T E Warkentin,et al.  Heparin-induced thrombocytopenia: a ten-year retrospective. , 1999, Annual review of medicine.

[39]  M. Monreal,et al.  Comparison of Subcutaneous Unfractionated Heparin with a Low Molecular Weight Heparin (Fragmin®) in Patients with Venous Thromboembolism and Contraindications to Coumarin , 1994, Thrombosis and Haemostasis.

[40]  R. Hull,et al.  Antithrombotic therapy for venous thromboembolic disease. , 1986, Chest.